GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » GlucoTrack Inc (NAS:GCTK) » Definitions » Ending Cash Position

GlucoTrack (GlucoTrack) Ending Cash Position : $4.50 Mil (As of Dec. 2023)


View and export this data going back to 2000. Start your Free Trial

What is GlucoTrack Ending Cash Position?

GlucoTrack's Ending Cash Position for the quarter that ended in Dec. 2023 was $4.50 Mil.

GlucoTrack's quarterly Ending Cash Position declined from Jun. 2023 ($8.78 Mil) to Sep. 2023 ($6.90 Mil) and declined from Sep. 2023 ($6.90 Mil) to Dec. 2023 ($4.50 Mil).

GlucoTrack's annual Ending Cash Position declined from Dec. 2021 ($6.11 Mil) to Dec. 2022 ($2.33 Mil) but then increased from Dec. 2022 ($2.33 Mil) to Dec. 2023 ($4.50 Mil).

GlucoTrack Ending Cash Position Historical Data

The historical data trend for GlucoTrack's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GlucoTrack Ending Cash Position Chart

GlucoTrack Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.48 9.89 6.11 2.33 4.50

GlucoTrack Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.33 1.01 8.78 6.90 4.50

GlucoTrack Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

GlucoTrack's Ending Cash Position for the fiscal year that ended in Dec. 2023 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=2.331+2.171
=4.50

GlucoTrack's Ending Cash Position for the quarter that ended in Dec. 2023 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=6.897+-2.395
=4.50

GlucoTrack Ending Cash Position Related Terms

Thank you for viewing the detailed overview of GlucoTrack's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

GlucoTrack (GlucoTrack) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » GlucoTrack Inc (NAS:GCTK) » Definitions » Ending Cash Position
Comparable Companies
LUCY SDCCQ ECIA AVGR IMTH RSCF WHSI STSS GMVDF NXGL ISRG XPAR:EL BDX XSWX:ALC TSE:7741 WST OCSE:COLO B RMD TSE:4543 XSWX:STMN
Traded in Other Exchanges
N/A
Address
301 Route 17 North, Suite 800, Rutherford, New Jersey, NJ, USA, 07070
Website
https://www.glucotrack.com
GlucoTrack Inc is a medical device company. It focuses on the design, development, and commercialization of non-invasive glucose monitoring devices for use by people with diabetes and pre-diabetics. The company has developed a non-invasive glucose monitor, the GlucoTrack model DF-F glucose monitoring device, which is designed to help people with diabetes and pre-diabetics obtain glucose level readings without the pain, inconvenience, and difficulty of conventional spot finger stick devices. It also focuses on developing a wireless module for transmission of measurement data captured by the GlucoTrack model DF-F to a cloud-based server.
Executives
James S Cardwell officer: Chief Financial Officer CLINTON SQUARE, 75 S. CLINTON AVE., SUITE 510, ROCHESTER NY 14604
Erin Catherine Carter director 301 RTE 17 NORTH, STE. 800, RUTHERFORD NJ 07070
Allen Danzig director 301 RT 17 NORTH, SUITE 800, RUTHERFORD NJ 07070
Shimon D Rapps director C/O ANDREW GARRETT, INC., 52 VANDERBILT AVENUE SUITE 510, NEW YORK NY 10017
Drew Sycoff director C/O ANDREW GARRETT INC, 52 VANDERBILT AVENUE - 20TH FLOOR, NEW YORK NY 10017
David Podwalski officer: Chief Commercial Officer 19 HA'YAHALOMIM ST., P.O. BOX 12163, ASHDOD L3 7760049
Michael Hauck director 19 HA'YAHALOMIM ST., P.O. BOX 12163, C/O INTEGRITY APPLICATIONS, INC., ASHDOD L3 7760049
John A Graham director, officer: Chief Executive Officer 19 HA'YAHALOMIM STREET, P.O. BOX 12163, ASHDOD L3 7760049
Sami Sassoun officer: Chief Financial Officer 39-06 ACKERMAN DRIVE, FAIR LAWN L3 7760049
Philip Darivoff director 1 FARMSTEAD ROAD, SHORT HILLS NJ 07078
Revan Schwartz director 19 HA'YAHALOMIM ST., P.O. BOX 12163, C/O INTEGRITY APPLICATIONS, INC., ASHDOD L3 7760049
Angela Strand Boydston director C/O AEROGEN, INC., 2071 STIERLIN COURT, MOUNTAIN VIEW CA 94043
Leslie Seff director PO BOX 59, 40 HELLBROOK LANE, ULSTER PARK NY 12487
Eran Hertz officer: Chief Financial Officer C/O INTEGRITY APPLICATIONS, INC., 102 HA'AVODA STREET, P.O. BOX 432, ASHKELON L3 L3 78100
Israel B. Ehrlich director C/O INTEGRITY APPLICATIONS, INC., 102 HA'AVODA STREET, P.O. BOX 432, ASHKELON L3 L378100